GC
OTLK icon

Grimes & Company’s Outlook Therapeutics OTLK Stock Holding History

Grimes & Company’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$3.94K – 354
2023
Q4 		$3.94K Hold
500
– – ﹤0.01% 331
2023
Q3 		$2.21K Hold
500
– – ﹤0.01% 310
2023
Q2 		$17.4K Hold
500
– – ﹤0.01% 311
2023
Q1 		$10.9K Hold
500
– – ﹤0.01% 301
2022
Q4 		$10.8K Hold
500
– – ﹤0.01% 294
2022
Q3 		$12K Hold
500
– – ﹤0.01% 270
2022
Q2 		$10K Buy
+500
New +$14.4K ﹤0.01% 273

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Grimes & Company's OTLK Position: Q1 2024 in Review

Grimes & Company sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 500 shares — an estimated $3.94K sold.

Grimes & Company first reported a position in OTLK in Q2 2022 and held it in 7 quarters. The position peaked at $17.4K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Grimes & Company reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Grimes & Company sold 500 Outlook Therapeutics shares in Q1 2024, an estimated $3.94K.
  • Grimes & Company first reported a position in Outlook Therapeutics in Q2 2022 and held it in 7 quarters.
  • Grimes & Company's Outlook Therapeutics position peaked at $17.4K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Grimes & Company's 13F filing for Q1 2024, filed 17 Apr 2024.